 Orgenesis NASDAQ:ORGS Inc announced the next phase of collaboration with Johns Hopkins University, which involves the construction of a cell and gene therapy processing facility for point of care POC treatment of patients at Johns Hopkins. Construction work is planned to start in the second quarter of 2022 and the facility is expected to be operational in 2Q 2023. 